Mucolytic Therapy in Tracheostomy Patients with COPD

Oral Mucolytic Therapy

• High-dose N-acetylcysteine (600 mg twice daily orally) reduces COPD exacerbation rates (RR 0.78) and is recommended by the American College of Chest Physicians for patients with moderate to severe COPD and a history of two or more exacerbations in the previous 2 years 1
• The European Respiratory Society suggests oral mucolytic therapy for patients with moderate or severe airflow obstruction to reduce hospitalizations and exacerbation frequency 2

Mechanism of Action and Safety Profile

• Acetylcysteine cleaves disulfide bonds in mucoproteins, reducing viscosity and making thick secretions easier to clear from the tracheobronchial tree, and is rapidly absorbed and quickly appears in active form in lung tissue and respiratory secretions 1
• Oral mucolytics are generally well tolerated with rare adverse gastrointestinal effects 1
• No evidence of increased adverse events compared to placebo in mucolytic therapy trials 2

Clinical Considerations

• For mechanically ventilated tracheostomy patients, maintaining a closed circuit with in-line suction minimizes aerosolization and infection risk 3, 4
• The European Respiratory Society guidelines provide the strongest support for mucolytic use in COPD patients with moderate to severe disease 5, 6